NYSE:ABT

Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

ABT shares closed at $128 on Oct. 15, down 3.5% for the day and about 2% for the week. Abbott reported Q3 revenue of $11.37 billion, up 6.9% year-over-year but slightly below estimates; adjusted EPS matched forecasts at $1.30. Medical Devices drove growth, while Diagnostics fell 6.6%. Investors sold off the stock after in-line results, with analysts maintaining a Hold rating and a $143.50 median price target.

15 October 2025

Earnings Reports·NYSE:ABT·Stock Market

Global Wearable Health Tech News – June and July 2025

Biobeat’s cuffless vital-sign patch received FDA clearance and CE marking for remote hospital monitoring. PharmaSens and SiBionics unveiled the niia™ signature patch, combining a continuous glucose monitor and insulin pump, at ADA 2025. Fasikl’s Felix NeuroAI Wristband became the first FDA-cleared neuromodulation wearable for essential tremor. U.S. HHS Secretary RFK Jr. launched the MAHA initiative for nationwide wearable adoption.

7 July 2025

NASDAQ:AAPL·NASDAQ:DXCM·NYSE:ABT·Technology

Previous 1 2 3

ASX Set to Dip as Middle East Tensions Boost Oil Prices; Premier Investments Reports Lower H1 Earnings
March 19, 2026, 9:22 PM EDT. Australian shares are expected to decline on Friday amid volatile energy markets triggered by Middle East strikes that briefly pushed Brent crude to $119 a barrel. The S&P 500 and Nasdaq each dropped 0.3%, while the Dow fell 0.4% overnight. Investors are also focused on Australia's upcoming consumer price index report. Premier Investments (ASX:PMV) posted fiscal first-half earnings of AU$0.6351 per share on AU$460.3 million revenue, down from AU$0.7307 earnings on AU$465.2 million a year earlier. Flight Centre Travel Group (ASX:FLT) acquired UK agency Fresh Approach, expanding its FCM meetings-and-events operations. The ASX benchmark closed down 1.7% at 8,497.80 on Thursday.